var path='https://www.tickertech.net'; function heading(heading) { document.write('

'+ ''+ '
• '+heading+'
'+ ''+ '

'); } function hiLite(imgDocID,imgObjName) { document.images[imgDocID].src = eval(imgObjName + ".src"); } function showStatus(toshow) { window.status = toshow; } function checkChoose() { if (document.choose.ticker.value == "") { alert("Please enter symbols before clicking the go button"); return false; } else return true; } function popJT(url,name){ var xwid = screen.width; xwid = xwid - 10; javaticker = window.open(url,name,'width='+xwid+',height=100,resizable=yes,scrollbars=no,toolbar=no,location=no,directories=no,status=yes,menubar=no'); javaticker.opener.name="opener"; //javaticker.moveTo(0,30); } var allow = 0; var ref = ""+location; if ((ref.indexOf("cryptocurrencieschannel.com") > 0) || (ref.indexOf("cefchannel.com") > 0) || (ref.indexOf("bdcinvestor.com") > 0) || (ref.indexOf("tickertech.com") > 0) || (ref.indexOf("xxxx:") > 0) || (ref.indexOf("javascript:") > 0) || (ref.indexOf("filseclab.com") > 0) || (ref.indexOf("msnscache.com") > 0) || (ref.indexOf("toolbar.google.com") > 0) || (ref.indexOf("etfchannel.com") > 0) || (ref.indexOf("marketnewsvideo.com") > 0) || (ref.indexOf("news.google.com") > 0) || (ref.indexOf("dividendchannel.com") > 0) || (ref.indexOf("www.google.com") > 0) || (ref.indexOf("energystockchannel.com") > 0) || (ref.indexOf("metalschannel.com") > 0) || (ref.indexOf("portfoliochannel.com") > 0) || (ref.indexOf("canadastockchannel.com") > 0) || (ref.indexOf("theonlineinvestor.com") > 0) || (ref.indexOf("investhelp.com") > 0) || (ref.indexOf("preferredstockchannel.com") > 0) || (ref.indexOf("stockoptionschannel.com") > 0) || (ref.indexOf("holdingschannel.com") > 0) || (ref.indexOf("tickertech.net") > 0) || (ref.indexOf("historicalstockprice.com") > 0) || (ref.indexOf("splithistory.com") > 0) || (ref.indexOf("stocksplithistory.com") > 0) || (ref.indexOf("google.c") > 0) || (ref.indexOf("208.71.46.190") > 0) || (ref.indexOf("search.yahoo") > 0) || (ref.indexOf("sharesoutstandinghistory.com") > 0) || (ref.indexOf("marketcaphistory.com") > 0) || (ref.indexOf("ytdreturn.com") > 0) || (ref.indexOf("averageannualreturn.com") > 0) || (ref.indexOf("redinews.com") > 0) || (ref.indexOf("technicalanalysischannel.com") > 0) || (ref.indexOf("stockdma.com") > 0) || (ref.indexOf("stockrsi.com") > 0) || (ref.indexOf("stockmacd.com") > 0) || (ref.indexOf("topdividends.com") > 0) || (ref.indexOf("monthlydividendpayingstocks.com") > 0) || (ref.indexOf("nextearningsdate.com") > 0) || (ref.indexOf("pastearnings.com") > 0) || (ref.indexOf("historicalperatio.com") > 0) || (ref.indexOf("historicalearnings.com") > 0) || (ref.indexOf("webcache.googleusercontent.com") > 0)) { allow = 1; } function ShowTTIPage() { if (allow) { document.write('\n'); } if (allow) { document.write('

\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('\n'); } if (allow) { document.write('
4/29 - 4:00 PM \; \;Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
4/10 - 8:03 AM \; \;Arcutis Appoints David Topper as Chief Financial Officer
4/5 - 4:00 PM \; \;Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/28 - 8:00 AM \; \;Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/11 - 8:00 AM \; \;Arcutis Promotes Todd Tucker to Chief Human Resources Officer
3/10 - 4:00 PM \; \;Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
3/9 - 4:00 PM \; \;New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
3/5 - 4:00 PM \; \;Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/4 - 4:00 PM \; \;Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
3/4 - 8:00 AM \; \;Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting
2/29 - 5:01 PM \; \;Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
2/28 - 11:31 PM \; \;Arcutis Announces Pricing of $150 Million Public Offering
2/28 - 4:10 PM \; \;Arcutis Announces Proposed Public Offering
2/28 - 4:00 PM \; \;Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
2/27 - 5:51 AM \; \;Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/16 - 8:00 AM \; \;Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
2/6 - 4:00 PM \; \;Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/31 - 8:00 AM \; \;Arcutis to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
1/29 - 8:00 AM \; \;Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
1/22 - 8:00 AM \; \;ZORYVE (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
more news
\n'); } if (!allow) { document.write(''+ ''+ '

Access Denied

'+ '

Please Read This Important Message

'+ ' If you are a paying TickerTech.com client and your account was not set up to include the configuration'+ ' received, please email support@tickertech.com,'+ ' or call us at 1-866-515-2082 to verify your account settings.'+ ' '+ '

'+ ' '+ ' Note! If you reached this page'+ ' after attempting to place a TickerTech.com product onto your web page, go no further; you must sign up as a'+ ' paying client. For pricing information please visit our products page, email '+ ' services@tickertech.com, or give us a call at 1-866-515-2082.'+ ' '+ '

'+ ' '+ ' TickerTech.com home
'+ ' TickerTech.com products'+ '
'+ ' '+ ''); } }